Abstract
The use of the nanotechnology in the development of new drugs has had in the last years a very widespread presence in the pharmaceutical industry. Diverse diseases that are treated by means of conventional administration systems as capsules, covered tablets or injectable not always have the therapeutic effect expected due to its bioavailability, solubility in aqueous medium and the stability of the excipients that they accompany to the drug. It is for this reason that the formation of nanoparticles either from organic sources as natural polymers like chitosan or synthetic like poly-ε-caprolactone (PCL) affording the inclusion of diverse liposoluble active compounds, they have given excellent results in the incipient treatment of behavior disorders that are necessary drugs that should remain close of active sites at the time. Thus, this review shows the formation of nanoparticles for a direct application of the psychiatric medication, may be considered as a new pharmacological tool by its low cytotoxicity and high efficiency.
Keywords: Mental disorders, Nanoparticles, Nanotechnology, Neurodegenerative diseases.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Nanoparticles in the Treatment of Mental Disorders: A New Tool in the Psychiatric Medication
Volume: 15 Issue: 4
Author(s): Eduardo Sobarzo-Sánchez, Seyed Mohammad Nabavi, Eugenio Uriarte and Lourdes Santana
Affiliation:
Keywords: Mental disorders, Nanoparticles, Nanotechnology, Neurodegenerative diseases.
Abstract: The use of the nanotechnology in the development of new drugs has had in the last years a very widespread presence in the pharmaceutical industry. Diverse diseases that are treated by means of conventional administration systems as capsules, covered tablets or injectable not always have the therapeutic effect expected due to its bioavailability, solubility in aqueous medium and the stability of the excipients that they accompany to the drug. It is for this reason that the formation of nanoparticles either from organic sources as natural polymers like chitosan or synthetic like poly-ε-caprolactone (PCL) affording the inclusion of diverse liposoluble active compounds, they have given excellent results in the incipient treatment of behavior disorders that are necessary drugs that should remain close of active sites at the time. Thus, this review shows the formation of nanoparticles for a direct application of the psychiatric medication, may be considered as a new pharmacological tool by its low cytotoxicity and high efficiency.
Export Options
About this article
Cite this article as:
Sobarzo-Sánchez Eduardo, Nabavi Mohammad Seyed, Uriarte Eugenio and Santana Lourdes, Nanoparticles in the Treatment of Mental Disorders: A New Tool in the Psychiatric Medication, Current Topics in Medicinal Chemistry 2015; 15 (4) . https://dx.doi.org/10.2174/1568026615666150108124533
DOI https://dx.doi.org/10.2174/1568026615666150108124533 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clearance of Beta-Amyloid in the Brain
Current Medicinal Chemistry Antifungal Therapy of Aspergillosis of the Central Nervous System and Aspergillus Endophthalmitis
Current Pharmaceutical Design A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design An Uncommon Case of Symptomatic Multiple Meningiomas with Bilateral Compressive Optic Neuropathy Rapidly Induced under Cyprotero ne Acetate Treatment
Current Drug Safety Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis
Central Nervous System Agents in Medicinal Chemistry Organic Cation Transporters: Physiology, Toxicology and Special Focus on Ethidium as a Novel Substrate
Current Drug Metabolism Astrocytes Exert and Control Immune Responses in the Brain
Current Immunology Reviews (Discontinued) The Blood-Brain Barrier in NeuroAIDS
Current HIV Research Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2)
Current Topics in Medicinal Chemistry Small Neuroscience: The Nanostructure of the Central Nervous System and Emerging Nanotechnology Applications
Current Nanoscience The Physiological Characteristics and Transcytosis Mechanisms of the Blood-Brain Barrier (BBB)
Current Pharmaceutical Biotechnology Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision
Anti-Cancer Agents in Medicinal Chemistry Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Brain-metastatic Breast Cancer: Clinical Considerations and Pharmacological Approaches
Anti-Cancer Agents in Medicinal Chemistry Aquaporins and Glia
Current Neuropharmacology Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology Curcumin Prevents Brain Damage and Cognitive Dysfunction During Ischemic-reperfusion Through the Regulation of miR-7-5p
Current Neurovascular Research Intrathecal Enzyme Replacement Therapy for Mucopolysaccharidosis I: Translating Success in Animal Models to Patients
Current Pharmaceutical Biotechnology Obstetric Anaesthesia and Obesity
Current Women`s Health Reviews